Menu
Not yet recruiting NCT07725718

Risk Factors for Mesh Infection After Abdominal Wall Reconstruction

Observational Incisional Hernia Ventral Hernia Parastomal Hernia Abdominal Wall Defect

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Incisional Hernia, Ventral Hernia, Parastomal Hernia, Abdominal Wall Defect. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Risk Factors for Mesh-Related Infection in Abdominal Wall Reconstruction: A Single-Centre Prospective Observational Cohort Study

Overview

Abdominal wall reconstruction (AWR) with mesh is the standard repair for ventral, incisional, parastomal and complex abdominal wall defects, but mesh-related infection remains one of its most serious complications - prolonging hospital stay, often requiring reoperation or removal of the mesh, and increasing the risk of hernia recurrence. Reported infection rates vary widely, and the independent contribution of individual risk factors remains uncertain, in large part because much of the existing evidence comes from retrospective series with inconsistent outcome definitions. This single-centre, prospective observational cohort study will enrol consecutive adults undergoing elective or urgent AWR with synthetic, biosynthetic or biological mesh at a tertiary referral hernia unit. Participants will be followed for 12 months on a fixed schedule (7-10 days, 30 days, 90 days, 6 months and 12 months). Using internationally accepted, prespecified definitions of mesh infection and surgical site occurrence, the study will collect up to 18 candidate patient, defect, operative and perioperative risk factors and analyse them by multivariable logistic regression to identify the independent predictors of mesh-related infection within 90 days of surgery. Secondary aims are to describe the incidence, timing, microbiology and management (salvage versus explantation) of mesh infection; to report surgical site occurrences and reoperation; and to derive an exploratory risk-stratification model. The findings are intended to support preoperative risk assessment, targeted patient optimisation, informed mesh and technique selection, and shared decision-making. The study is designed and reported in accordance with the STROBE statement.

Detailed description

Design and setting. A prospective, single-centre observational cohort study conducted at a tertiary referral hernia and abdominal wall surgery unit (Department of Surgery, Faculty of Medicine, Minia University, Egypt). Consecutive eligible adults undergoing AWR with mesh are enrolled at the time of surgery and followed prospectively. No study-specific intervention is imposed; surgical and perioperative management follow routine unit practice, and exposures (candidate risk factors) are observed rather than assigned.

Study period. The study runs for 24 months in total, from 15 August 2026 to 15 August 2028. Consecutive enrolment takes place over the first 12 months (15 August 2026 - 15 August 2027); each participant is then followed for 12 months, so that the last enrolled participant completes follow-up at the end of month 24. The 90-day primary-outcome window closes for the final participant in November 2027.

Objectives. The primary objective is to identify the independent risk factors associated with mesh-related infection within 90 days of AWR. Secondary objectives are to estimate the cumulative incidence and timing of mesh infection; to characterise its microbiology and the proportion managed by mesh salvage versus partial or complete explantation; to describe surgical site occurrence (SSO) and SSO requiring procedural intervention (SSOPI); to derive an exploratory, prespecified risk-stratification model and assess its discrimination and calibration; and to evaluate the association of mesh infection with hernia recurrence and reoperation at 12 months.

Primary outcome. Mesh-related infection within 90 days, confirmed by at least one of: purulent drainage from a peri-mesh space in contact with the prosthesis; positive microbiological culture from peri-mesh fluid, explanted mesh or an image-guided/operative peri-mesh specimen; cross-sectional imaging (preferably contrast-enhanced CT) demonstrating a peri-mesh collection or abscess with clinical signs of infection; or the need for operative or percutaneous intervention directed at infected mesh. Superficial incisional infection without mesh involvement is recorded separately, and deep or organ/space infection is coded using CDC/NHSN criteria.

Candidate predictors. Up to 18 prespecified variables across four domains - patient (age, sex, BMI/obesity, active smoking, diabetes and HbA1c, serum albumin, ASA class, immunosuppression, COPD), defect (defect width by EHS grouping, recurrent hernia, loss of domain, CDC wound class, VHWG grade, stoma/parastomal defect), operative (mesh type and position, component separation including transversus abdominis release, operative time, concomitant bowel procedure, estimated blood loss, drain use) and perioperative (antibiotic-prophylaxis appropriateness, intraoperative normothermia and glycaemia, transfusion, early SSO).

Follow-up. Participants are reviewed at baseline/operation and at 7-10 days, 30 days, 90 days (primary outcome), 6 months and 12 months. Outcome events are adjudicated against the prespecified definitions by two investigators, with disagreements resolved by consensus.

Sample size and analysis. Target enrolment is 420 participants (≈380 evaluable after ≈10% attrition; ≈53 expected events), sized to support a stable multivariable logistic regression model (events-per-variable ≥10) and precise estimation of infection incidence. Candidate predictors are analysed by univariable tests and multivariable logistic regression with adjusted odds ratios and 95% confidence intervals; Firth penalised likelihood or LASSO is used where events are limited. Model discrimination (c-statistic) and calibration (Hosmer-Lemeshow test, calibration plot) are assessed with optimism-corrected internal validation by bootstrapping. Prespecified secondary and sensitivity analyses include time-to-event modelling and subgroup analyses by mesh type, mesh position and wound contamination class.

Primary outcome measures

  • Incidence of mesh-related infection within 90 days of abdominal wall reconstruction [Time frame: Within 90 days after surgery]
Secondary outcome measures (9)
  • Cumulative incidence and timing of mesh-related infection [Time frame: Through 12 months after surgery]
  • Microbiology of mesh-related infection [Time frame: Through 12 months after surgery]
  • Management of mesh infection: salvage versus explantation [Time frame: Through 12 months after surgery]
  • Incidence of surgical site occurrence (SSO) [Time frame: 30 days, 90 days and 12 months after surgery]
  • Incidence of SSO requiring procedural intervention (SSOPI) [Time frame: 30 days, 90 days and 12 months after surgery]
  • Incidence of surgical site infection [Time frame: 30 days after surgery]
  • Incidence of hernia recurrence [Time frame: 12 months after surgery]
  • Incidence of unplanned reoperation related to the index repair [Time frame: 12 months after surgery]
  • Performance of the exploratory risk-stratification model [Time frame: At completion of follow-up and analysis (up to 42 months)]

Eligibility criteria

Inclusion criteria

  • Adults aged ≥18 years.
  • Undergoing elective or urgent abdominal wall reconstruction with implantation of synthetic, biosynthetic or biological mesh for a ventral, incisional, parastomal or complex abdominal wall defect.
  • Able and willing to provide written informed consent and to attend scheduled follow-up.

Exclusion criteria

  • Suture-only repair without mesh.
  • Inguinal or femoral (groin) hernia repair.
  • Active systemic sepsis or established intra-abdominal mesh infection at the time of index surgery.
  • Mesh placed solely for a non-reconstructive indication (e.g. temporary abdominal closure or planned re-look without definitive reconstruction).
  • Estimated life expectancy < 12 months or inability to complete the minimum follow-up.
  • Patient declines participation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Egypt · 1 center
  • Minia University Hospitals - Department of Surgery, Faculty of Medicine, Minia University — Minya

Identifiers

NCT: NCT07725718 · 2057:7/2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗